Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine
- 16 September 2004
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 55 (2), 179-188
- https://doi.org/10.1007/s00280-004-0868-0
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agentsInternational Journal of Cancer, 1999
- The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell lineCancer Letters, 1998
- The bis benzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoproteinAnti-Cancer Drugs, 1998
- Pharmacological considerations in the modulation of multidrug resistanceEuropean Journal Of Cancer, 1996
- Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical OutcomeNew England Journal of Medicine, 1995
- Tetrandrine: A new ligand to block voltage-dependent Ca2+ and Ca2+-activated K+ channelsLife Sciences, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Clinical Correlates of MDR1 (P-glycoprotein) Gene Expression in Ovarian and Small-Cell Lung CarcinomasJNCI Journal of the National Cancer Institute, 1992
- Systemic Toxic Effects Associated With High-Dose Verapamil Infusion and Chemotherapy AdministrationJNCI Journal of the National Cancer Institute, 1991
- Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.Journal of Histochemistry & Cytochemistry, 1990